Free Trial

Salarius Pharmaceuticals (SLRX) Competitors

Salarius Pharmaceuticals logo
$0.76 -0.03 (-4.29%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$0.72 -0.04 (-5.44%)
As of 08:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SLRX vs. TCRT, SNPX, CHRO, TSBX, BMRA, TRAW, OBSV, CYCC, JBIO, and CLDI

Should you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Alaunos Therapeutics (TCRT), Synaptogenix (SNPX), Chromocell Therapeutics (CHRO), Turnstone Biologics (TSBX), Biomerica (BMRA), Traws Pharma (TRAW), ObsEva (OBSV), Cyclacel Pharmaceuticals (CYCC), Jade Biosciences (JBIO), and Calidi Biotherapeutics (CLDI). These companies are all part of the "pharmaceutical products" industry.

Salarius Pharmaceuticals vs. Its Competitors

Alaunos Therapeutics (NASDAQ:TCRT) and Salarius Pharmaceuticals (NASDAQ:SLRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

In the previous week, Salarius Pharmaceuticals had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for Salarius Pharmaceuticals and 0 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.00 equaled Salarius Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Alaunos Therapeutics Neutral
Salarius Pharmaceuticals Neutral

Alaunos Therapeutics' return on equity of -169.34% beat Salarius Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -169.34% -124.28%
Salarius Pharmaceuticals N/A -324.13%-174.40%

Alaunos Therapeutics has a beta of -0.79, indicating that its stock price is 179% less volatile than the S&P 500. Comparatively, Salarius Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.

Alaunos Therapeutics has higher revenue and earnings than Salarius Pharmaceuticals. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos Therapeutics$10K821.64-$4.68M-$2.54-1.97
Salarius PharmaceuticalsN/AN/A-$5.58M-$4.82-0.16

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 11.9% of Salarius Pharmaceuticals shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 1.2% of Salarius Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Alaunos Therapeutics beats Salarius Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Get Salarius Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLRX vs. The Competition

MetricSalarius PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.68M$2.39B$5.51B$8.95B
Dividend YieldN/A1.80%5.25%4.04%
P/E Ratio-0.169.2627.9920.16
Price / SalesN/A590.63411.53174.36
Price / CashN/A161.3437.0657.97
Price / Book0.804.638.145.62
Net Income-$5.58M$31.26M$3.16B$248.50M
7 Day Performance-15.04%5.50%3.14%4.49%
1 Month Performance2.73%3.01%3.46%7.03%
1 Year Performance-72.43%1.89%34.19%21.07%

Salarius Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLRX
Salarius Pharmaceuticals
0.7107 of 5 stars
$0.76
-4.3%
N/A-72.3%$1.68MN/A-0.1620News Coverage
Gap Up
TCRT
Alaunos Therapeutics
0.4847 of 5 stars
$4.85
-5.5%
N/A-21.4%$8.41M$10K-1.9140
SNPX
Synaptogenix
1.1689 of 5 stars
$7.85
+29.8%
$14.00
+78.3%
+82.2%$8.40MN/A-0.784High Trading Volume
CHRO
Chromocell Therapeutics
N/A$1.26
-6.7%
N/A-87.9%$8.31MN/A-1.024Gap Up
TSBX
Turnstone Biologics
1.5665 of 5 stars
$0.36
+1.8%
$0.45
+25.3%
-84.0%$8.16M$19.31M-0.1382High Trading Volume
BMRA
Biomerica
0.39 of 5 stars
$3.16
+0.3%
N/A-1.6%$8.02M$5.41M-1.3660
TRAW
Traws Pharma
0.1073 of 5 stars
$1.48
+3.5%
N/AN/A$7.96M$230K-0.0517Gap Up
OBSV
ObsEva
N/AN/AN/AN/A$7.94M$20.11M-0.1150
CYCC
Cyclacel Pharmaceuticals
0.7452 of 5 stars
$0.33
-0.2%
N/A-99.0%$7.86M$40K-0.0114Stock Split
JBIO
Jade Biosciences
2.1821 of 5 stars
$9.99
+8.7%
$14.00
+40.1%
N/A$7.72MN/A0.0020Gap Down
CLDI
Calidi Biotherapeutics
0.4805 of 5 stars
$0.23
+2.8%
N/A-53.5%$7.31M$50K0.0038News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:SLRX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners